Abstract
Infection is a major cause of morbidity and mortality in intensive care units (ICU). The impact on prognostic of an inadequate antibiotic therapy is well established. The problem is due to the growing spread of resistant microorganisms, including both Gram-negative and Gram-positive pathogens, especially in the case of ICU-acquired infections. In this context, antibiotics with broad spectrum activity are usually required. Moreover, these antibiotics should reach high concentrations in tissues, especially in lungs, and should exert a bactericidal activity for the most severely ill patients, especially those with bloodstream infections. A frequent problem in clinical practice is the lack of data validating their use in the context of critically ill patients. In the present article, we review the newest antibiotics that could be of interest for severe ICU-acquired infections: tigecycline, moxifloxacine, the newer carbapenems, linezolide and daptomycine. We discuss their approved indications and identify the fields in which they could be used to treat infections acquired in the ICU.
Keywords: New antibiotics, severity, acquired infections, intensive care, ICU-acquired infections, linezolide and daptomycine, spectrum beta-lactamase-producing enterobacteriaceae (ESBLE), bloodstream infections, Haemophilus influenza, Nosocomial bloodstream infections, tetracyclineresistant isolates, Stenotrophomonas maltophilia, pharmacokinetic, alkaline phosphatase, tigecyclin, hemodialysis
Infectious Disorders - Drug Targets
Title: New Antibiotics for Severe ICU-Aquired Bacterial Infections
Volume: 11 Issue: 4
Author(s): Julien Poissy and Eric Senneville
Affiliation:
Keywords: New antibiotics, severity, acquired infections, intensive care, ICU-acquired infections, linezolide and daptomycine, spectrum beta-lactamase-producing enterobacteriaceae (ESBLE), bloodstream infections, Haemophilus influenza, Nosocomial bloodstream infections, tetracyclineresistant isolates, Stenotrophomonas maltophilia, pharmacokinetic, alkaline phosphatase, tigecyclin, hemodialysis
Abstract: Infection is a major cause of morbidity and mortality in intensive care units (ICU). The impact on prognostic of an inadequate antibiotic therapy is well established. The problem is due to the growing spread of resistant microorganisms, including both Gram-negative and Gram-positive pathogens, especially in the case of ICU-acquired infections. In this context, antibiotics with broad spectrum activity are usually required. Moreover, these antibiotics should reach high concentrations in tissues, especially in lungs, and should exert a bactericidal activity for the most severely ill patients, especially those with bloodstream infections. A frequent problem in clinical practice is the lack of data validating their use in the context of critically ill patients. In the present article, we review the newest antibiotics that could be of interest for severe ICU-acquired infections: tigecycline, moxifloxacine, the newer carbapenems, linezolide and daptomycine. We discuss their approved indications and identify the fields in which they could be used to treat infections acquired in the ICU.
Export Options
About this article
Cite this article as:
Poissy Julien and Senneville Eric, New Antibiotics for Severe ICU-Aquired Bacterial Infections, Infectious Disorders - Drug Targets 2011; 11 (4) . https://dx.doi.org/10.2174/187152611796504854
DOI https://dx.doi.org/10.2174/187152611796504854 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Methadone and the Heart: What the Clinician Needs to Know
Current Drug Abuse Reviews ARC - Augmented Renal Clearance
Current Pharmaceutical Biotechnology Pharmacology of Cyclic Peptides: Vancomycin and Oxytocin as Paradigms
Protein & Peptide Letters Bivalirudin: Alternative Anticoagulation During Cardiopulmonary Bypass in Patients with Heparin-Induced Thrombocytopenia
Recent Patents on Cardiovascular Drug Discovery Infection and Anemia
Infectious Disorders - Drug Targets Aminoglycoside Nephrotoxicity
Current Drug Targets - Infectious Disorders Continuous Infusion of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Point of Care Cardiac Ultrasound Applications in the Emergency Department and Intensive Care Unit - A Review
Current Cardiology Reviews Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Perceval Sutureless Valve – are Sutureless Valves Here?
Current Cardiology Reviews Molecular Dynamics Simulations of Novel Potential Inhibitors for Penicillin Binding Protein 2B of the Resistant 5204 Strain of Streptococcus pneumoniae
Current Computer-Aided Drug Design Occurrence and Clinical Impact of Microembolic Signals (MES) in Patients with Chronic Cardiac Diseases and Atheroaortic Plaques - A Systematic Review
Current Vascular Pharmacology β-Lactams in the New Millennium. Part-II: Cephems, Oxacephems, Penams and Sulbactam
Mini-Reviews in Medicinal Chemistry Calcific Aortic Stenosis: Molecular and Cellular Mechanisms, Medical Treatment Alternatives
Current Cardiology Reviews Outpatient Treatment of Hemorrhoidal Disease: The Alternative Way to Treat Hemorrhoidal Disease in a Simple, Safe and Effective Manner
Reviews on Recent Clinical Trials Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Evaluation of <sup>99m</sup>Technetium-Vancomycin Imaging Potential in Experimental Rat Model for the Diagnosis of Infective Endocarditis
Current Medical Imaging Antibiotic Dosage Regimens in Respiratory Tract Infections in the Pharmacokinetic/Pharmacodynamic Era
Current Respiratory Medicine Reviews